'indian ip and liabilities law barrier to pharma r&d investment'
.
erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
.
.
.
treatment delays are also causing needless anxiety and distress to patients as well as putting lives at serious risk.
.
.